Relmada Therapeutics (RLMD) Earnings Analysis

Relmada Therapeutics (RLMD) next reports earnings on 2026-08-06, consensus EPS -0.21 USD. Last quarter (2026-03-19) it missed with EPS -0.27 USD vs -0.14 USD est (-92.9%). It has beaten estimates in 0/3 recent quarters (0%). Trailing P/E -4.50.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does RLMD next report earnings?

Next earnings date2026-08-06
Consensus EPS estimate-0.21 USD
Revenue estimaten/a

RLMD earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-03-19-0.27 USD-0.14 USD-92.9%Miss
2025-11-13-0.3 USD-0.04 USD-650%Miss
2025-05-12-0.58 USD-0.31 USD-87.1%Miss

Beat rate: 0/3 (0%) over reported quarters with consensus data.

RLMD valuation and analyst view

Trailing P/E-4.50
Trailing EPS-0.67991 USD
Price / book1.98
Dividend yield0.00%
Market cap0.52B
Analyst consensusBuy (5 buy / 2 hold / 1 sell)
Avg price target12 USD

Related research pages

Frequently asked questions

When is Relmada Therapeutics (RLMD)'s next earnings date?

Relmada Therapeutics is next scheduled to report on 2026-08-06, with a consensus EPS estimate of -0.21 USD.

Did RLMD beat earnings last quarter?

In its 2026-03-19 report, RLMD posted EPS of -0.27 USD versus a -0.14 USD estimate — a miss of 92.9%.

What is RLMD's earnings track record?

Over the last 3 reported quarters with consensus data, RLMD beat estimates 0 times (0%).

What is RLMD's current P/E ratio and EPS?

RLMD trades at a trailing P/E of -4.50 on trailing EPS of -0.679905081561086 USD.

What do analysts rate RLMD?

Analyst consensus is "Buy" across 8 ratings (0 strong buy, 5 buy, 2 hold, 1 sell, 0 strong sell). Average 12-month price target: 12 USD.